
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3719116/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders. Neuropsychopharmacology, 2022, 47, 420-421.	2.8	2
2	Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial. Biological Psychiatry, 2022, 91, 550-560.	0.7	9
3	Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?. Molecular Psychiatry, 2022, 27, 1095-1102.	4.1	52
4	A primary care first (PCP-first) model to screen and treat depression: A VitalSign6 report from a second cohort of 32,106 patients. General Hospital Psychiatry, 2022, 74, 1-8.	1.2	5
5	Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant. International Journal of Neuropsychopharmacology, 2022, 25, 85-88.	1.0	4
6	Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory. Translational Psychiatry, 2022, 12, 16.	2.4	5
7	Quantification of brain age using high-resolution 7 tesla MR Imaging and implications for epilepsy. Epilepsy and Behavior Reports, 2022, 18, 100530.	0.5	0
8	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. Journal of Psychiatric Research, 2022, 149, 243-251.	1.5	4
9	Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 20-28.	1.1	6
10	Association of anger attacks with suicidal ideation in adults with major depressive disorder: Findings from the EMBARC study. Depression and Anxiety, 2021, 38, 57-66.	2.0	7
11	Quality of life after response to acute-phase cognitive therapy for recurrent depression. Journal of Affective Disorders, 2021, 278, 218-225.	2.0	6
12	Design and rationale of an intelligent algorithm to detect BuRnoUt in HeaLthcare workers in COVID era using ECG and artificiaL intelligence: The BRUCEE-LI study. Indian Heart Journal, 2021, 73, 109-113.	0.2	10
13	Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. Drug Design, Development and Therapy, 2021, Volume 15, 151-157.	2.0	6
14	Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. Journal of Psychopharmacology, 2021, 35, 124-127.	2.0	2
15	Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome. Psychiatric Quarterly, 2021, 92, 1069-1077.	1.1	0
16	Sex-specific differences in the association between body mass index and brain aging in young adults: Findings from the human connectome project. Psychoneuroendocrinology, 2021, 124, 105059.	1.3	8
17	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry, 2021, 178, 193-202.	4.0	122
18	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. Journal of Affective Disorders, 2021, 282, 602-610.	2.0	3

#	Article	IF	CITATIONS
19	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life. Journal of Clinical Psychiatry, 2021, 82, .	1.1	6
20	Neurocircuit Mechanisms of Active Suicidal Ideation in Youths and Young Adults: Findings From the T-Rad Study. Biological Psychiatry, 2021, 89, S82.	0.7	0
21	Functional Neuroimaging Moderators of Improvement in Irritability With Antidepressants vs. Placebo in Adults With Major Depressive Disorder: Findings From the EMBARC Study. Biological Psychiatry, 2021, 89, S47.	0.7	Ο
22	Association Between Habenular Volume and Hemoglobin A1c in Young Adults Differs on the Basis of Smoking Status: Findings From the Human Connectome Project. Biological Psychiatry, 2021, 89, S271-S272.	0.7	0
23	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. American Journal of Psychiatry, 2021, 178, 437-446.	4.0	33
24	Whole-Transcriptome Brain Expression and Exon-Usage Profiling in Major Depression and Suicide. Biological Psychiatry, 2021, 89, S120-S121.	0.7	0
25	Irritability Partly Accounts for the Association Between Pain and Depression: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project. Biological Psychiatry, 2021, 89, S91.	0.7	Ο
26	Sex-Specific Differences in the Association Between Obesity and Depression in Large Epidemiological Studies: Findings From Dallas Heart Study and National Health and Nutrition Examination Survey. Biological Psychiatry, 2021, 89, S340.	0.7	0
27	Vortioxetine Versus Placebo for Major Depressive Disorder. Journal of Clinical Psychiatry, 2021, 82, .	1.1	16
28	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology, 2021, 46, 2266-2277.	2.8	19
29	Smoking status links habenular volume to glycated hemoglobin: Findings from the Human Connectome Project-Young Adult. Psychoneuroendocrinology, 2021, 131, 105321.	1.3	4
30	Irritability as an independent predictor of concurrent and future suicidal ideation in adults with stimulant use disorder: Findings from the STRIDE study. Journal of Affective Disorders, 2021, 292, 108-113.	2.0	5
31	Dysfunction of default mode network is associated with active suicidal ideation in youths and young adults with depression: Findings from the T-RAD study. Journal of Psychiatric Research, 2021, 142, 258-262.	1.5	10
32	COVID 19-related burnout among healthcare workers in India and ECG based predictive machine learning model: Insights from the BRUCEE- Li study. Indian Heart Journal, 2021, 73, 674-681.	0.2	10
33	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 2020, 25, 1592-1603.	4.1	235
34	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. American Journal of Psychiatry, 2020, 177, 143-154.	4.0	76
35	Dysfunctional adaptive immune response in adolescents and young adults with suicide behavior. Psychoneuroendocrinology, 2020, 111, 104487.	1.3	26
36	Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder. JAMA Psychiatry, 2020, 77, 397.	6.0	45

#	Article	IF	CITATIONS
37	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). Journal of Psychiatric Research, 2020, 122, 22-32.	1.5	21
38	Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. International Clinical Psychopharmacology, 2020, 35, 313-321.	0.9	9
39	Neural Correlates of Irritability and Suicidality in Adult Outpatients With Major Depressive Disorder: Findings From the EMBARC Study. Biological Psychiatry, 2020, 87, S312.	0.7	о
40	Irritability as an Independent Predictor of Suicidality: Findings From Four Clinical Trials of Adults With Either Major Depressive Disorder or Stimulant Use Disorder. Biological Psychiatry, 2020, 87, S73.	0.7	0
41	Sex Differences in Dysfunctional Th2 Immune Response With Suicidality. Biological Psychiatry, 2020, 87, S336-S337.	0.7	Ο
42	Association of Anger Attacks With Persistently Elevated Suicidality in Depressed Patients: Do Early Improvements in Irritability Reduce the Risk?. Biological Psychiatry, 2020, 87, S108-S109.	0.7	0
43	Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study. Psychiatric Research and Clinical Practice, 2020, 2, 10-18.	1.3	7
44	Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder. Neuropsychopharmacology, 2020, 45, 2147-2154.	2.8	26
45	Neural Circuits Linking Irritability and Anger Attacks in Major Depressive Disorder: Findings From EMBARC Study. Biological Psychiatry, 2020, 87, S72.	0.7	Ο
46	Childhood maltreatment and impact on clinical features of major depression in adults. Psychiatry Research, 2020, 293, 113412.	1.7	26
47	Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. Journal of Affective Disorders, 2020, 277, 478-485.	2.0	4
48	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2020, 126, 19-25.	1.5	14
49	Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals, 2020, 13, 116.	1.7	78
50	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. Depression and Anxiety, 2020, 37, 771-783.	2.0	22
51	Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. Psychological Medicine, 2020, , 1-9.	2.7	6
52	Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study. Journal of Affective Disorders, 2020, 275, 44-47.	2.0	9
53	An electroencephalographic signature predicts antidepressant response in major depression. Nature Biotechnology, 2020, 38, 439-447.	9.4	157
54	Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depression and Anxiety, 2020, 37, 485-495.	2.0	9

#	Article	IF	CITATIONS
55	180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. CNS Spectrums, 2020, 25, 313-314.	0.7	0
56	What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI. Journal of Clinical Psychiatry, 2020, 81, .	1.1	10
57	Efficacy of Esketamine Augmentation in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	1.1	71
58	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 82, .	1.1	6
59	Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. Psychological Medicine, 2019, 49, 1118-1127.	2.7	109
60	F143. Do Age and Sex Moderate the Association of Inflammatory Cytokines and Anhedonia in Major Depressive Disorder? Findings From CO-MED Trial. Biological Psychiatry, 2019, 85, S268.	0.7	0
61	Differential prediction of antidepressant treatment response via measurement of baseline adiponectin level: findings from the CO-MED randomized clinical trial. Journal of Affective Disorders, 2019, 254, 132-133.	2.0	0
62	A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. Annals of Family Medicine, 2019, 17, 326-335.	0.9	32
63	224. Sex Differences in Association of Inflammation and Suicidality: Findings From Two Separate Cohorts of Patients With Major Depressive Disorder. Biological Psychiatry, 2019, 85, S93.	0.7	0
64	S90. Association of Autoimmunity With Dysfunctional Th2-Mediated Immune Response in Major Depressive Disorder. Biological Psychiatry, 2019, 85, S331-S332.	0.7	0
65	133. Baseline Functional Connectivity and Cerebral Perfusion Markers of Response to Sertraline Vs. Placebo: A Data-Driven Multi-Modal Neuroimaging Study. Biological Psychiatry, 2019, 85, S55-S56.	0.7	0
66	O14. Cerebral Blood Perfusion Predicts Response to Antidepressant Treatment in Major Depressive Disorder. Biological Psychiatry, 2019, 85, S111.	0.7	0
67	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. Nature Human Behaviour, 2019, 3, 1319-1331.	6.2	29
68	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. Journal of Psychopharmacology, 2019, 33, 185-193.	2.0	14
69	VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression. Pharmaceuticals, 2019, 12, 71.	1.7	33
70	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. EClinicalMedicine, 2019, 10, 32-41.	3.2	19
71	57. Dysfunctional Th2-Cell Mediated Adaptive Immune Response is Associated With Suicide Behavior in Adolescents and Young Adults. Biological Psychiatry, 2019, 85, S24.	0.7	0
72	When Discontinuing SSRI Antidepressants Is a Challenge: A Response to Letters to the Editor. American Journal of Psychiatry, 2019, 176, 488-489.	4.0	4

#	Article	IF	CITATIONS
73	Exploring the Association of Sex Differences and Exposure to Maternal Smoking With Low Fetal Growth. JAMA Psychiatry, 2019, 76, 766.	6.0	0
74	Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. International Journal of Neuropsychopharmacology, 2019, 22, 339-348.	1.0	7
75	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. Journal of Psychiatric Research, 2019, 113, 165-171.	1.5	33
76	Screening and Management of Depression in Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 1827-1845.	1.2	182
77	Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. American Journal of Psychiatry, 2019, 176, 358-366.	4.0	39
78	Improving the identification and treatment of depression in low-income primary care clinics: a qualitative study of providers in the VitalSign6 program. International Journal for Quality in Health Care, 2019, 31, 57-63.	0.9	13
79	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. Focus (American) Tj ETQq1 1 0.784	314 rgBT / 0.4	Overlock 10
80	Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial. Pharmaceuticals, 2019, 12, 184.	1.7	10
81	Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. Journal of Affective Disorders, 2019, 242, 87-95.	2.0	14
82	Anti-Inflammatory Treatments for Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	6
83	Discontinuing Antidepressants. Journal of Clinical Psychiatry, 2019, 80, .	1.1	6
84	Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. Journal of Affective Disorders, 2018, 234, 34-37.	2.0	50
85	Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality. Journal of Affective Disorders, 2018, 235, 45-51.	2.0	32
86	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. Journal of Psychiatric Research, 2018, 102, 207-215.	1.5	12
87	154. Gender-Specific Association of IL-17 with Anhedonia in Depressed Outpatients: Findings From CO-MED Trial. Biological Psychiatry, 2018, 83, S63.	0.7	0
88	A pilot program for implementing mental health screening, assessment, and navigation in a communityâ€based cancer center. Psycho-Oncology, 2018, 27, 683-686.	1.0	5
89	Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. Journal of Affective Disorders, 2018, 233, 3-14.	2.0	116
90	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimulation, 2018, 11, 75-84.	0.7	20

#	Article	IF	CITATIONS
91	5.68 Factors Related to Disorganized Attachment Style of Trauma-Affected Young Children in a Therapeutic Daycare Setting. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, S249.	0.3	0
92	156. Inflammation Selectively Impairs Executive Function in Treatment-Resistant Depressed Outpatients: Findings From TREAD Study. Biological Psychiatry, 2018, 83, S63-S64.	0.7	0
93	When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. American Journal of Psychiatry, 2018, 175, 1176-1184.	4.0	47
94	Pharmacogenomics and Biomarkers of Depression. Handbook of Experimental Pharmacology, 2018, 250, 101-113.	0.9	11
95	Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. Molecular Neuropsychiatry, 2018, 4, 7-19.	3.0	12
96	Association of T and non-T cell cytokines with anhedonia: Role of gender differences. Psychoneuroendocrinology, 2018, 95, 1-7.	1.3	34
97	68. Blood Brain Barrier Dysfunction Selectively Predicts Poorer Outcomes With SSRI Monotherapy vs. Antidepressant Combinations: Clinical Utility of Novel Astrocytic Marker. Biological Psychiatry, 2018, 83, S28.	0.7	1
98	Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial. Personalized Medicine in Psychiatry, 2018, 9-10, 1-7.	0.1	5
99	Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. International Journal of Neuropsychopharmacology, 2018, 21, 325-332.	1.0	27
100	Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation. International Journal of Molecular Sciences, 2018, 19, 233.	1.8	60
101	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. Psychotherapy and Psychosomatics, 2018, 87, 285-295.	4.0	39
102	Experimental Therapies for Treatment-Resistant Depression: Deciding When to Go to an Unproven or Experimental Therapy. Focus (American Psychiatric Publishing), 2018, 16, 279-284.	0.4	4
103	Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. Neuropsychopharmacology, 2018, 43, 2197-2203.	2.8	12
104	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology, 2017, 78, 105-113.	1.3	155
105	Is C-reactive protein ready for prime time in the selection of antidepressant medications?. Psychoneuroendocrinology, 2017, 84, 206.	1.3	16
106	Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial. Journal of Psychiatric Research, 2017, 94, 1-6.	1.5	23
107	317. Screening for Auto-Antibodies with Antidepressant Medications Using Glomerular Proteomic Microarray Arrays: Findings from CoMed Clinical Trial. Biological Psychiatry, 2017, 81, S130-S131.	0.7	1
108	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. Brain, Behavior, and Immunity, 2017, 66, 103-110.	2.0	60

#	Article	IF	CITATIONS
109	1.5 Factors Impacting the Resilience of Trauma-Affected Young Children in a Therapeutic Daycare Setting. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, S153-S154.	0.3	0
110	Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination. International Journal of Neuropsychopharmacology, 2017, 20, 919-927.	1.0	29
111	Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 3001-3010.	1.0	3
112	Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 803-813.	1.0	21
113	Implementing mental health screening, assessment, and navigation program in a community-based survivorship program Journal of Clinical Oncology, 2017, 35, 36-36.	0.8	1
114	Teaching Motivational Interviewing Skills to Psychiatry Trainees: Findings of a National Survey. Academic Psychiatry, 2016, 40, 149-152.	0.4	6
115	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. Journal of Clinical Psychiatry, 2016, 77, 1036-1042.	1.1	15
116	Commentary: Clinical Approach to the Differential Diagnosis between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. Frontiers in Psychiatry, 2016, 7, 23.	1.3	0
117	IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY. Depression and Anxiety, 2016, 33, 870-881.	2.0	31
118	3.50 STUDY OF TRAUMA-AFFECTED YOUNG CHILDREN IN A THERAPEUTIC DAYCARE SETTING. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S158.	0.3	0
119	Attitudes Towards Substance Use Disorders and Association with Motivational Interviewing Education: A Survey of Psychiatry Chief Residents. Academic Psychiatry, 2016, 40, 523-524.	0.4	2
120	COMT val158met polymorphism and molecular alterations in the human dorsolateral prefrontal cortex: Differences in controls and in schizophrenia. Schizophrenia Research, 2016, 173, 94-100.	1.1	8
121	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. American Journal of Psychiatry, 2016, 173, 1196-1204.	4.0	40
122	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. Journal of Affective Disorders, 2016, 206, 17-22.	2.0	26
123	Altered GABA neurotransmission in major depressive disorder: Re-analyzing publicly available data. European Neuropsychopharmacology, 2016, 26, 796.	0.3	2
124	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. PLoS ONE, 2016, 11, e0167901.	1.1	26
125	A Case of Frontotemporal Dementia Presenting With Treatment-Refractory Psychosis and Extreme Violence. Journal of Clinical Psychopharmacology, 2015, 35, 732-733.	0.7	10
126	Training Psychiatry Residents at Correctional Facilities. Academic Psychiatry, 2015, 39, 123-124.	0.4	2

MANISH KUMAR JHA

#	Article	IF	CITATIONS
127	Availability and Attitudes Toward Correctional Psychiatry Training: Results of a National Survey of Training Directors. Journal of Behavioral Health Services and Research, 2014, 41, 244-250.	0.6	9
128	Improvement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder. Journal of Affective Disorders, 2014, 167, 37-43.	2.0	14
129	Can We Address the Shortage of Psychiatrists in the Correctional Setting with Exposure During Residency Training?. Community Mental Health Journal, 2012, 48, 756-760.	1.1	11
130	Post adoption depression. Archives of Women's Mental Health, 2010, 13, 147-151.	1.2	34